Tone mix
Week by week 50 weeks
Share of Intellia Therapeutics, Inc's 162 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Jan 12, 2026 · tone +100Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen+107
- Week of Aug 11, 2025 · tone -100Wedbush Lowers Earnings Estimates for Intellia Therapeutics-95
- Week of Dec 1, 2025 · tone -100Intellia Therapeutics (NASDAQ:NTLA) Downgraded to "Sell" Rating by Wall Street Zen-90
- Week of Aug 24, 2026 · tone +100Intellia Therapeutics (NASDAQ:NTLA) Receives "Market Outperform" Rating from Citizens Jmp+88
- Week of Sep 15, 2025 · tone +99Intellia Therapeutics Shares Are Ripping Higher: Here's Why+77
- Week of May 4, 2026 · tone -32Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying-75
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Intellia Therapeutics, Inc in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 3 | 0 |
| Last 30 sessions | 10 | 0 |
| Last 90 sessions | 37 | +29 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 29, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.manilatimes.net · 1 outletIntellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026Neutral
- www.manilatimes.net · 1 outletIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026 | www.manilatimes.net | 1 | Neutral |
| Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletCritical Contrast: Intellia Therapeutics (NASDAQ:NTLA) vs. Neurogene (NASDAQ:NGNE)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Critical Contrast: Intellia Therapeutics (NASDAQ:NTLA) vs. Neurogene (NASDAQ:NGNE) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 19, 2026
3 headlines, average tone 0: 0 positive, 3 neutral and 0 negative. Showing all 3.
- www.dailypolitical.com · 1 outletIntellia Therapeutics (NASDAQ:NTLA) vs. BeyondSpring (NASDAQ:BYSI) Head to Head SurveyNeutral
- www.tickerreport.com · 1 outletContrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)Neutral
- www.themarketsdaily.com · 1 outletFinancial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)Neutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Intellia Therapeutics (NASDAQ:NTLA) vs. BeyondSpring (NASDAQ:BYSI) Head to Head Survey | www.dailypolitical.com | 1 | Neutral |
| Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI) | www.tickerreport.com | 1 | Neutral |
| Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 14, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.rttnews.com · 1 outletIntellia Therapeutics Names New CMO To Oversee Clinical And Regulatory FunctionsNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Intellia Therapeutics Names New CMO To Oversee Clinical And Regulatory Functions | www.rttnews.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 13, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletIntellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical OfficerNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Intellia Therapeutics, Inc, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.